ST九芝(000989.SZ):2023年,公司OTC產品合計實現營業收入15.05億元
格隆匯5月27日丨ST九芝(000989.SZ)在投資者互動平台表示,2023年,公司疏血通注射液、六味地黃丸、安宮牛黃丸、驢膠補血顆粒、足光散、阿膠、逍遙丸等七個品種的銷售收入過億。疏血通注射液、斯奇康、裸花紫珠片單品的營業收入可以分別參考公司全資子公司友搏藥業、斯奇生物、海南九芝堂的營業收入,分別為6.02億元、0.66億元以及0.47億元。2023年,公司OTC產品合計實現營業收入15.05億元,處方藥產品合計實現營業收入13.28億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.